Seer, Inc.NASDAQ: SEER

Seer Board of Directors Issues Letter to Shareholders Demonstrating the Strength and Experience of Seer’s Director Nominees

· Issued by Seer, Inc. via GlobeNewswire

Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card

REDWOOD CITY, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) ("Seer" or the "Company") today issued a letter to stockholders containing important information for shareholders to consider in connection with the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders as of May 29, 2026 will be entitled to vote at the Annual Meeting.

The Board recommends that stockholders vote "FOR" the election of Seer's seven highly qualified nominees on the BLUE proxy card.

The full text of the letter follows:

Dear Fellow Seer Stockholder,

At our upcoming Annual Meeting of Stockholders on July 28, 2026, your vote is critical to the continued success of Seer.

Seer has a purpose-built Board of Directors with the expertise needed to guide a category-creating life sciences tools company. This Board is committed to overseeing our strategy to pioneer the nascent space of proteomics using the Board's decades of industry knowledge and insight.

At the Annual Meeting, Bradley Radoff and Michael Torok are attempting to replace three of your Board's sitting directors - Seer's Co-Founder, CEO and Chair Omid Farokhzad, M.D., Terrance McGuire and Dipchand (Deep) Nishar - with candidates who bring no proteomics experience, no life sciences tools experience and no platform operating experience. Radoff and Torok have offered no plan to build Seer. Their only desire is to strip Seer of its cash. Additionally, their nominees raise serious concerns regarding independence and their ability to act in the best interests of all stockholders.

The Three Directors that Radoff and Torok Are Trying to Remove Are Critical to Seer's Future

Omid Farokhzad, M.D.
Co-Founder, CEO and Chair;
Director since 2017

✓ Scientific architect of the
Proteograph® Product Suite
✓ Founder of multiple life
sciences platform companies
✓ Author of 200+ scientific
papers and inventor on 250+
patents
✓ Seer's largest long-term
stockholder, together with
family entities

Terrance McGuire
Founding Partner of Polaris
Partners; Director since 2017

✓ Decades of healthcare
investing and company-
building experience
✓ Proven capital allocation
and governance judgment
✓ Investor in Seer at
inception and again at Seer's
IPO
✓ One of Seer's longest-term
stockholders

Dipchand (Deep) Nishar
Technology and Growth
Leader; Director since 2021

✓ Former Senior Managing
Partner at SoftBank Vision
Fund
✓ Former Managing Director
at General Catalyst
✓ Former senior executive at
LinkedIn and Google
✓ Deep capital markets,
growth investing and
corporate strategy expertise